Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BGF MDI HFO vs HFA in Healthy Adults
NCT06723756Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable concentration and Maximum observed plasma concentration. Started Jan 2025; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06723756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723756.